Thus, growing evidence supports the notion of productive STING signaling in myeloid cells and cancer cells, however the anti-tumor effects of STING activation in these cell types via a targeted STINGa delivery approach, such as an antibody-drug conjugate (ADC) has not been studied. This evidence concerns the gene STING1 and cancer.